Second Genome and Mayo Clinic Enter Collaboration to Develop Microbiome Therapeutics in Multiple Diseases
October 7, 2014, South San Francisco, CASecond Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, has entered into an extensive partnership with the Mayo Clinic Center for Individualized Medicine to support the development of therapeutic products for multiple disease indications, starting with inflammatory bowel disease, metabolic disorders, and colorectal cancer.
Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Scientific Officer
September 9, 2014, South San Francisco, CASecond Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has appointed Karim Dabbagh, Ph.D., as the company’s Chief Scientific Officer. In this new position, Dr. Dabbagh will be responsible for the company’s drug pipeline, fueled by Second Genome’s novel discovery platform for identifying and validating microbiome-mediated drug targets and therapeutics.
Second Genome Enters Into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity
May 2, 2014, South San Francisco, CASecond Genome announced today that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes, in order to better understand the inter-relationship between the microbiome, obesity and metabolic disorders.